Influence of vaccine potency and booster administration of foot-and-mouth disease vaccines on the antibody response in calves with maternal antibodies

Can Çokçalıskan1,*, Tunçer Türkoğlu1, Ergün Uzunlu1, Beyhan Sareyyupoğlu1, İbrahim Hancı1, Ahmet İpek1, Abdullah Arslan1, Ayca Babak2, Gülnur İldeniz3, Veli Gülyaz1

1Institute of Foot and Mouth Disease (SAP), 2Directorate-General for Agriculture and Rural Development, and 3Directorate-General for State Farms, Ministry of Food, Agriculture and Livestock, Ankara 06044, Turkey

Foot-and-mouth disease is one of the most important viral diseases of cloven-hoofed animals. Mass vaccination is an effective method to control the disease and is frequently utilized in endemic regions. Sufficient protection of young animals is important in mass vaccination campaigns. Maternal antibodies negatively affect the success of vaccination. Hence, determination of the optimal vaccination age is crucial for the uninterrupted protection of young animals. This study was performed to identify the effect of vaccine potency and booster administration on serum neutralizing antibody titers of calves with different levels of maternal antibodies. Calves (n = 111) on a state farm were used in this study. Oil adjuvant foot-and-mouth disease vaccines with 3 PD50 and 6 PD50 potencies were used with or without booster administration. Serum samples were collected each month up to day 120 postvaccination. Virus neutralization tests were used to measure the serum neutralizing antibody titers and estimate the protection period by using pre-determined cut-off values for protection. The results revealed that a vaccination with a 6 PD50 potency vaccine, preferably followed by a booster dose, should be used to overcome maternal immunity for incessant protection.

Keywords: calf, foot-and-mouth disease, high potency vaccine, maternal antibody, virus neutralization

Introduction

Foot-and-mouth disease (FMD) is one of the most important viral diseases of cloven-hoofed animals. The causative agent is in the Aphthovirus genus, a member of the picornavirus family. Mortality from FMD is high in young animals due to the affinity of the virus for myocardial tissue [24]. In addition, great economic losses occur due to trade restrictions in and with countries where the disease is present. Mass vaccination is an effective method to control FMD and is frequently utilized in endemic regions [15].

Sufficient protection of young animals is an important issue in mass vaccination campaigns [19] given that susceptible young animals can aggravate outbreaks [9]. In cattle, passive transfer of antibodies from dam to neonate is possible via colostrum, which is crucial for protection against many calf diseases. The dam’s age affects the amount and quality of colostrum and thereby the antibody titer circulating in calf serum [7].

An inadequate immune response in young animals in many livestock species (pigs, cattle, and horses) has been reported [20]. Some immune response-related problems are associated with the vaccination of neonates, including the neonate’s immature immune system and the presence of maternal antibodies transferred from the dam [3,20]. Moreover, frequent vaccinations may lead to tolerance to antigens, and a high level of cortisones can negatively affect immunization responses in neonatal calves [3].

The presence of maternal antibodies decreases or may completely disappear after immunization of neonates. This outcome is observed with all types of vaccines, and there are numerous reports [1,8,10,23] demonstrating that the presence of maternal antibodies affects immunization responses negatively. In theory, a vaccine should be administered after maternal antibodies have completely disappeared [20]. Many factors are involved in the duration of the presence of maternal
antibodies in neonates. It is difficult to predict when maternal antibody disappearance is complete; therefore, measurement of antibody level in a neonate is necessary. However, in practice, it is difficult to measure the antibody level of each individual. Hence, a prime-boost vaccination strategy is used to overcome maternal antibody interference [5,20,22,24]. An oil adjuvant vaccine can overcome maternal interference via a single immunization [21]. The same study suggested that vaccines with an aluminum hydroxide adjuvant cannot overcome maternal immunity [21].

According to European Pharmacopeia [4], the minimum protective level of an FMD vaccine cannot be less than 3 PD50. In addition, vaccines with a 6 PD50 protective level can be used in emergency situations. When a double emulsion vaccine of 3 PD30 potency is used in a vaccination campaign, 71% of the vaccinated livestock population are protected, whereas vaccination with the same vaccine but with a 6 PD30 potency confers 81% protection [14]. In a vaccine efficacy study, a single dose of immunization can only prevent 69% of clinical FMD and 83% of severe symptoms [15]. Vaccination campaigns with > 3 PD30 oil adjuvant vaccines have been used in Turkey to combat FMD, but recently, that strategy was replaced with one that uses a 6 PD50 vaccine.

The minimum age of animals to be vaccinated during a vaccination campaign, the potency of the vaccine, and the booster dose necessary to overcome maternal antibody interference have yet to be determined. The aim of this study was to investigate the antibody response of calves with various levels of maternal antibodies to single and booster immunizations with FMD vaccines of different potencies.

Materials and Methods

Vaccine

Two different batches of commercial Turvac-oil FMD trivalent vaccine of 3 PD50 and 6 PD50 potencies for type A virus, produced by the SAP Institute, Turkey, were used in this study. Montanide ISA 206, (Seppic, France) oil adjuvant was used to prepare double emulsions (water-in-oil-in-water). The O TUR 07, ATUR 04/06 (A IRAN 2005), and ASIA-1TUR 11 inactivated virus cultures were used as antigens. The 3 PD50 potency vaccine contained 4 µg of type A antigen per dose, whereas the 6 PD50 potency vaccine contained 8.4 µg of type A antigen per dose. Both vaccines also contained 5 µg of type O antigens (3 PD30) and 3 µg of ASIA-1 antigens (3 PD50) per dose. The potencies of the vaccines were previously determined by vaccination-animal challenge experiments described in the 2011 World Organisation for Animal Health (OIE) manual [27].

Animals

One hundred eleven calves owned by a state farm in Konya/Turkey were used in the study. The dams had been vaccinated periodically (at four-month intervals) against FMD several times before the study started. The calves were kept together in paddocks on the farm as a beef herd under regular management practices. All calves received pooled colostrum from recent dams during their first three days. The calves were weaned at 2.5 months of age. The ages of the calves ranged from 64 to 153 days at the time of the primary vaccination. Calf breeds were Holstein-Friesian and Swiss Brown. The study was undertaken in accordance with the International Harmonization of Animal Care and Use guidelines. The study protocol was approved by the ethics committee of the SAP Institute (Ankara, Turkey) (approval No. 2016-03).

Immunization and sampling

Initially, animals were randomly assigned to four groups. Each group consisted of 25 to 29 animals. Groups A and B received 3 PD50 potency vaccines, whereas groups C and D received 6 PD50 vaccines. Additionally, five unvaccinated animals were used as a maternal antibody control group and used to monitor the natural decay of the maternal antibodies. Before vaccine administration, blood samples were obtained from the caudal vein by using sterile vacuum tubes and needles. Two milliliters of vaccine was injected intramuscularly into the hind leg of each animal. Twenty-eight days after the first vaccination, groups B and D received booster doses of the initial vaccine. Blood samples were taken on day 0 and additional blood samples were obtained on days 28, 60, 90, and 120 postvaccination (pv). Sera were stored at −20°C until the time of analysis. Based on the neutralizing maternal antibody titers on day 0, the initial four groups were reorganized to form a total of 12 sub-groups to evaluate the effect of the maternal antibody level on the response to vaccination (Table 1).

Virus neutralization test

The virus neutralization test was performed as described in the 2011 OIE manual [27]. Briefly, two-fold serial dilutions of heat-inactivated serum samples from 1:4 to 1:512 were prepared by using Glasgow cell culture medium (Biochrome; Merck, Germany) in a microplate. Subsequently, equal amounts of a 100 TCID50 ATUR 04/06 working virus suspension was added to each well. After one hour of incubation at 37°C, a suspension of 6 × 105 BHK-21 cells/mL was added in equal volumes to each well. After incubation at 37°C for 72 h, the wells were observed under a microscope to observe cytopathic effects, as characterized by the presence of cell lysis. The neutralizing antibody titer was expressed as the log10 serum...
dilution that neutralized 50% of the virus. The assay’s validity is periodically assessed by inter-laboratory validation tests among European laboratories working with the FMD virus.

Table 1. Study groups according to vaccine potency, booster dose, and initial antibody level

| Number | Group | Starting maternal antibody titre (VNT, log_{10}) | Number of animals |
|--------|-------|-----------------------------------------------|-------------------|
| 1      | A     | < 1.50 (low)                                  | 8                 |
| 2      | B     | < 1.50 (low)                                  | 10                |
| 3      | C     | < 1.50 (low)                                  | 7                 |
| 4      | D     | < 1.50 (low)                                  | 8                 |
| 5      | A     | 1.50–1.80 (medium)                            | 12                |
| 6      | B     | 1.50–1.80 (medium)                            | 6                 |
| 7      | C     | 1.50–1.80 (medium)                            | 6                 |
| 8      | D     | 1.50–1.80 (medium)                            | 11                |
| 9      | A     | > 1.80 (high)                                 | 7                 |
| 10     | B     | > 1.80 (high)                                 | 12                |
| 11     | C     | > 1.80 (high)                                 | 12                |
| 12     | D     | > 1.80 (high)                                 | 7                 |
| 13     | Unvaccinated | > 1.80 (high)                               | 5                 |

VNT, virus neutralization test. Group A, 3 PD_{50} single dose; Group B, 3 PD_{50} with booster; Group C, 6 PD_{50} single dose; Group D, 6 PD_{50} with booster. Experimental groups of vaccinated and unvaccinated calves were initially established according to the potency of the vaccine (3 PD_{50} or 6 PD_{50}) and booster administration (A, B, C, and D). Later, the A–D groups were divided according to antibody titer level (low, medium, and high).

Kinetics of maternal antibody decay

Geometric mean titer values of the five animals in the unvaccinated group were calculated. To quantify maternal antibody decay, which is a process similar to a biochemical reaction, the natural logarithm (Ln) values of the mean antibody titers of the unvaccinated animals were plotted against time (days). Given the linear relationship, the decay reaction was illustrated to conform to 1st order reaction kinetics. Hence, the mean half-life of maternal antibodies was calculated from the slope of the linear graphic. The following formula was used:

\[ t_{1/2} = \frac{\ln 2}{k} , \]

where \( t_{1/2} \) is the half-life, \( k \) is the slope of the linear curve or the reaction coefficient with units in \( \text{day}^{-1} \), and \( \ln \) is the natural logarithm. Another decay curve was drawn (panel B in Fig. 1) to show the geometric mean of the neutralizing antibody titer values of the animals grouped by ten-day intervals (such as 60–70, 70–80, etc.) from the first sampling day to reveal the relationship between age at first sampling and maternal antibody level.

Data analysis

SPSS software for Windows (ver. 19; IBM, USA) was used for statistical analysis of the data. Analysis of variance (ANOVA) was used to examine differences between samplings. Tukey’s test was used to compare group data. Differences were considered significant if the \( p \) value was less than 0.05.

![Fig. 1.](image-url)
Results

Decay of maternal antibodies

Panel A in Fig. 1 illustrates the distribution of the neutralizing antibody titer values of calves in their first sampling and shows that several calves were carrying maternal antibodies at first sampling. The maternal antibody titers of the unvaccinated group gradually decreased and the decay reaction of the maternal antibodies conformed to 1st order reaction kinetics. The calculated mean half-life ($t_{1/2}$) of the maternal antibodies was 25.4 days according to the formula in the “Kinetics of maternal antibody decay” section. The linear relationship between titer level and time (days) is presented in panel C in Fig. 1. The $R^2$ for that relationship was 0.9993, and the reaction coefficient was 0.0273 day$^{-1}$. The slope of the geometric mean of the neutralizing antibody results for the first calf sampling period revealed that the maternal antibody titers of the calves dropped to a critical level of protection approximately 110 days after birth (panel B in Fig. 1).

Neutralizing antibody response of animals receiving a single dose of 3 PD$_{50}$ vaccine

After primary vaccination, a decrease in antibody levels was observed in all groups vaccinated with 3 PD$_{50}$ vaccine. Initially, for the group with the highest antibody level (> 1.80 log$_{10}$) vaccinated with a single dose of 3 PD$_{50}$ vaccine, the arithmetic mean antibody titer was 2.24 log$_{10}$. That value reduced to 1.49 log$_{10}$ on day 28 after primary vaccination and decreased to a level below the protective level at day 90 pv (panel C in Fig. 2). The group with an initial low antibody level (< 1.50 log$_{10}$) responded slightly to vaccination with the single dose of 3 PD$_{50}$ vaccine, but the group’s antibody levels remained below the protective level throughout the period of study (panel A in Fig. 2). The mean virus neutralizing (VN) antibody level of group 1 on day 60 pv was significantly lower than that in all groups (groups 2, 3, and 4) with same initial VN antibody level ($p < 0.05$). There was no statistically significant difference between the mean VN antibody level of groups 5 and 6 ($p < 0.05$).

![Fig. 2. Arithmetic means of serum virus neutralizing antibody titers of calves vaccinated with 3 PD$_{50}$ vaccine.](image-url)

Journal of Veterinary Science
Neuralizing antibody response of animals receiving two doses of 3 PD$_{50}$ vaccine

The initial arithmetic mean antibody titer was for the group with the highest antibody level ($> 1.80 \log_{10}$) was $2.26 \log_{10}$. After primary vaccination with 3 PD$_{50}$ vaccine, this value reduced to $1.47 \log_{10}$ at day 28 pv, at which time a booster dose was administered. One month following the booster dose, the titer increased to $1.84 \log_{10}$ (panel F in Fig. 2). In the low initial antibody level group ($< 1.50 \log_{10}$), the highest antibody titer was $2.02 \log_{10}$ one month after booster vaccination (panel D in Fig. 2), which was the highest level obtained by any application of the 3 PD$_{50}$ vaccine. Although the high antibody group vaccinated with the 3 PD$_{50}$ booster conferred protection from the beginning, the subsequent antibody level was reduced below the protective level before day 120 pv (panel E in Fig. 2). The antibody response level of the medium level maternal antibody group (1.5 to 1.8 log$_{10}$) vaccinated with the 3 PD$_{50}$ booster was below that of the high maternal antibody group, and the mean titers in the medium level group remained higher than the protective threshold throughout the study (panel E in Fig. 2).

Neutralizing antibody response of animals receiving a single dose of 6 PD$_{50}$ vaccine

After primary vaccination, a decrease in antibody levels was observed in all groups vaccinated with the 6 PD$_{50}$ vaccines. The initial arithmetic mean antibody titers was $2.11 \log_{10}$ for the group with the highest antibody level ($> 1.80 \log_{10}$). After vaccination with the 6 PD$_{50}$ vaccine, this titer was reduced to $1.52 \log_{10}$ (panel C in Fig. 3). The initial arithmetic mean value of the maternal antibodies in the low antibody group ($< 1.50 \log_{10}$) was $0.95 \log_{10}$. After primary vaccination, the mean antibody titer was $0.86 \log_{10}$. Subsequently, the mean titer increased to $1.81 \log_{10}$ on day 60 pv and was reduced to $1.38 \log_{10}$ at four months pv. A protection gap was noted in this group prior to day 60 pv (panel A in Fig. 3). There were no significant differences in VN antibody titers between the 3 PD$_{50}$ booster groups (groups 2, 6, and 10) and the 6 PD$_{50}$ single dose groups (groups 3, 7, and 11) at day 60 pv ($p < 0.05$).

Neutralizing antibody response of animals receiving two doses of 6 PD$_{50}$ vaccine

In the group with the highest antibody level ($> 1.80 \log_{10}$),
the initial geometric mean antibody titer was 2.15 log$_{10}$. After primary vaccination with the 6 PD$_{50}$ vaccine, this titer was reduced to 1.25 log$_{10}$ at day 28 pv. Booster administration of the 6 PD$_{50}$ vaccine at day 28 pv increased the titer to 2.19 log$_{10}$ on day 60 pv (panel F in Fig. 3). The initial arithmetic mean maternal antibody level in the low antibody group (< 1.50 log$_{10}$) was 1.15 log$_{10}$. After primary vaccination, the mean antibody titer was 0.82 log$_{10}$, which was the lowest value observed in this study (panel D in Fig. 3). The highest antibody response of the whole study (2.48 log$_{10}$ on day 60 pv) was also obtained in this low maternal antibody group (panel D in Fig. 3). All groups that received the booster exhibited a strong response that started one month after booster administration and persisted for more than four months above the protective level (panels D, E, and F in Fig. 3). The mean VN antibody levels of groups 4 and 8 on day 60 pv were significantly higher than those in all groups administered with a single 3 PD$_{50}$ dose (groups 1, 5, and 9) ($p < 0.05$). The mean VN antibody level of group 12 on day 60 pv was significantly higher than those in groups 1 and 5 ($p < 0.05$).

**Discussion**

Vaccine is an important weapon in the fight against FMD in endemic countries. Unfortunately, vaccination with present-day, conventional vaccines provides short-term, serotype-specific protection [12]. In addition, protection from FMD is mainly dependent on vaccine effectiveness because other measures, such as animal movement restrictions or biosecurity exercises, are difficult to apply in many countries including Turkey [16]. Vaccination of young cattle provides ambiguous results as the time of vaccination, maternal antibody level, breed of animal, and adjuvants used may affect the antibody response [13].

This study was performed in calves of various ages and with varying antibody titers in a farm implementing periodic FMD vaccinations to mimic field conditions. Two different FMD vaccine potencies were investigated in calves with various levels of maternal antibodies. Additionally, the effect of booster dose administration was evaluated for both vaccine potencies. The neutralizing antibody responses of calves with ages ranging from 64 days to 153 days prior to primary vaccination and with or without booster were measured. Various levels of maternal antibodies were detected in calves born to regularly vaccinated dams. Because the dams’ ages were heterogeneous hence each individual might have received different number of FMD vaccinations prior to the study.

Determination of the half-life of maternal antibodies is important because it enables estimation of the duration of protection [18]. Previous studies revealed that the average half-life of maternal antibodies was approximately 21 to 22 days [6,19,25]. Murphy et al. [18] reported that the half-life of IgG is 28.5 days in colostrum-fed calves. In this study, the mean half-life of the maternal antibody was 25.4 days. Our result is lower than those of Murphy et al. [18] but greater than those of Nicholls et al. [19] (22 days), Späth et al. [25] (21 days), and Dekker et al. [6] (21 days). The differences among these results might be attributed to the methods used to determine half-life, as was previously suggested by Murphy et al. [18]. The virus neutralization assay is an ideal method for investigating maternal interference [2]. It has been hypothesized that B cell epitopes are masked by a high level of neutralizing antibodies. However, monoclonal antibody experiments have revealed that the mechanism is more complex, and that steric hindrance may be involved [20]. Calves with high maternal antibody levels respond to primary and secondary vaccinations with low neutralizing antibody levels, and this is independent of the total antibody response, which includes antibodies other than the neutralizing antibodies [2]. Although the presence of maternal antibodies inhibits the primary humoral response to the vaccine, B cells are able to maintain their other functional capabilities, such as differentiation to memory cells [11]. That trait can be exploited to overcome maternal interference. A booster dose can invoke memory B cells, and there are many examples of this in practice [5,17,26]. In this study, booster administration showed its effect, particularly in the 3 PD$_{50}$ group in the presence of high and low antibody influence. Moreover, the highest titers observed in this study were obtained after a 6 PD$_{50}$ vaccine booster application.

One of the most important aspects of the antibody response in neonates is the ratio of antigen concentration to maternal antibody concentration [22]. Based on our results, the antigen amount per dose, as well as the provision of a booster dose, were important parameters in overcoming maternal antibody interference. In addition, the results revealed that it is impossible to obtain a robust antibody response with a 3 PD$_{50}$ vaccine, even with a low maternal antibody titer, with only a primary vaccination. This situation may be explained either by the presence of insufficient antigen in the 3 PD$_{50}$ vaccine for the immature immune system of young animals or the low antibody titers may not be low enough to overcome the interference. The latter is concordant with another study [24], which postulated that even trace amounts of maternal antibodies might block a strong response to FMD vaccine. Späth et al. [25] reported a similar situation with a commercial vaccine that passed potency tests in adult animals but failed to elicit strong total antibody titers, as detected with liquid phase-blocking ELISA, in calves. In the current study, as expected, the highest antibody level was obtained for the low maternal antibody level group that received primary and booster vaccines of 6 PD$_{50}$ potency. Normally, it is expected that high antibody levels would suppress at least the primary antibody response and the protective period would be short. But, interestingly, the longevities of the estimated protection of the groups with high maternal antibody levels were better than those in the medium and low maternal antibody
level groups for both the 3 and 6 PD50 vaccines. Similar results were obtained by Lee et al. [17] in piglets. Those authors suggested that the better response in smaller piglets might be a result of an overdose effect, given that smaller piglets receive more antigens per kilogram. As illustrated in panel A in Fig. 1, younger calves tended to have higher levels of maternal antibodies than older calves. This tendency could be due to the comparatively low weight of the younger group, as suggested by Lee et al. [17]. According to our study results, the immune response to a single dose 6 PD50 vaccine in the high-level maternal antibody group provided antibody titers greater than the protective level and for a long period of time. On the other hand, the protective periods were short for groups with initial low and medium maternal antibody levels. Therefore, it can be said that in high levels of maternal antibodies, which may be suppressed slightly by a high potency vaccine, the waning of maternal antibodies will take a long time and will remain greater than the protective level. Similarly, Späth et al. [25] reported a slight decrease at day 15 pv. The same authors observed a strong antibody response that persisted for four months in animals 3 to 4 months of age with low maternal antibody levels. In this study, the lowest values on day 28 pv were obtained in the low maternal antibody groups. At day 28 pv, all vaccinated groups had fewer neutralizing antibodies compared with the unvaccinated group. However, at day 60 pv, a significant difference in the neutralizing titers from the maternal antibody group was demonstrated for all groups except the 3 PD50 single dose group.

Comparing the 6 PD50 single and the 3 PD50 booster groups, there was a similar response pattern in the groups with high and low levels of initial maternal antibodies. However, in the medium level group, a slightly better response was obtained for the single 6 PD50 compared with vaccinations with 3 PD50 vaccines and with booster administration. According to our results, > 6 PD50 vaccines can be used not only in emergency situations but also for immunization of calves to overcome maternal interference.

Many animals carry maternal antibodies against FMD in their first few months of life in countries where mass vaccination is practiced and the disease displays an endemic character. Young animals can negatively influence herd immunity due to maternal antibody interference and vaccines with insufficient potency. Vaccines with high potency induce better immunity in dams, and more antibodies can then be transferred by colostrum. Despite interference, vaccination with a high potency vaccine, including a booster dose in the presence of a high level of neutralizing maternal antibodies, resulted in uninterrupted immunity in the calves in this study. Although it is recommended to administer a booster dose one month after primary vaccination in calves, it is not always possible for veterinarians to visit the same farm a second time in one month. Hence, dams should be vaccinated in late pregnancy. In addition, high potency vaccines should be used for immunization of calves older than 3 months of age, and, if possible, a high potency booster dose should be administered for continuous protection.

Acknowledgments

The authors thank Fuat Özyörük for useful advice and Banu Bayrı Özligate, Müslüm Kaan Arıcı, and Aysenur Ulusoy for their excellent technical help. This work was supported by The Republic of Turkey, Ministry of Food, Agriculture and Livestock, General Directorate of Agricultural Research and Policy (grant No. TAGEM/HSGYAD/15/A02/P02/54).

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Bielefeldt-Ohmann H, Prow NA, Wang W, Tan CS, Coyle M, Douma A, Hobson-Peters J, Kidd L, Hall RA, Petrovsky N. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Vet Res 2014, 45, 130.
2. Bucafusco D, Di Giacomo S, Pega J, Jancos MS, Schammas JM, Pérez-Fligueira M, Capozzo AV. Influence of antibodies transferred by colostrum in the immune responses of calves to current foot-and-mouth disease vaccines. Vaccine 2014, 32, 6576-6582.
3. Chase CC, Hurley DJ, Reber AJ. Neonatal immune development in the calf and its impact on vaccine response. Vet Clin North Am Food Anim Pract 2008, 24, 87-104.
4. Council of Europe, European Pharmacopoeia Commission, European Directorate for the Quality of Medicines & Healthcare. European Pharmacopoeia. 8th ed. Council of Europe, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, 2013.
5. Davis EG, Bello NM, Bryan AJ, Hankins K, WIlkerson M. Characterisation of immune responses in healthy foals when a multivalent vaccine protocol was initiated at age 90 or 180 days. Equine Vet J 2015, 47, 667-674.
6. Dekker A, Eblé P, Stockhofe N, Chénard G. Intratypic heterologous vaccination of calves can induce an antibody response in presence of maternal antibodies against foot-and-mouth disease virus. BMC Vet Res 2014, 10, 127.
7. Downey ED, Tait RG Jr, Mayes MS, Garrick DJ, Ridpath J, Reece JM. Effects of calf age and dam age on circulating BVDV II antibody levels prior to vaccination in Angus weaning calves. Reports No. 214. Iowa State Research Farm Progress Reports (US), Ames, 2011.
8. Ellis J, Gow S, Bolton M, Burdett W, Nordstrom S. Inhibition of priming for bovine respiratory syncytial virus-specific protective immune responses following parenteral vaccination of passively immune calves. Can Vet J 2014, 55, 1180-1185.
9. Einkev E, Zamir L, Hand F, Even Tov B, Klement E. Risk
factors for foot and mouth disease outbreaks in grazing beef cattle herds. Prev Vet Med 2015, 120, 236-240.
10. Endsley JJ, Roth JA, Ridpath J, Neill J. Maternal antibody blocks humoral but not T cell responses to BVDV. Biologicals 2003, 31, 123-125.
11. Foote MR, Nonnecke BJ, Beitz DC, Waters WR. Antigen-specific B-cell responses by neonatal calves after early vaccination. J Dairy Sci 2007, 90, 5208-5217.
12. Guzman E, Taylor G, Charleston B, Ellis SA. Induction of a cross-reactive CD8$^+$ T cell response following foot-and-mouth disease virus vaccination. J Virol 2010, 84, 12375-12384.
13. Hodgens DC, Shewen PE, Dewey CE. Influence of age and maternal antibodies on antibody responses of neonatal piglets vaccinated against Mycoplasma hyopneumoniae. J Swine Health Prod 2004, 12, 10-16.
14. Jamal SM, Bouma A, van den Broek J, Stegeman A, Chénard G, Dekker A. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle. Vaccine 2008, 26, 6317-6321.
15. Knight-Jones TJ, Bulut AN, Gubbins S, Stärk KD, Pfeiffer DU, Sumption KJ, Paton DJ. Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey. Vaccine 2014, 32, 1848-1855.
16. Knight-Jones TJ, Gubbins S, Bulut AN, Stärk KD, Pfeiffer DU, Sumption KJ, Paton DJ. Mass vaccination, immunity and coverage: modelling population protection against foot-and-mouth disease in Turkish cattle. Sci Rep 2016, 6, 22121.
17. Lee HS, Lee NH, Seo MG, Ko YJ, Kim B, Lee JB, Kim JS, Park S, Shin YK. Serological responses after vaccination of growing pigs with foot-and-mouth disease trivalent (type O, A and Asia1) vaccine. Vet Microbiol 2013, 164, 239-245.
18. Murphy JM, Hague JV, Chigerwe M. Comparison of serum immunoglobulin G half-life in dairy calves fed colostrum, colostrum replacer or administered with intravenous bovine plasma. Vet Immunol Immunopathol 2014, 158, 233-237.
19. Nicholls MJ, Black L, Rweyemamu MM, Genovese J, Ferrari R, Hammant CA, de Silva E, Umehara O. The effect of maternally derived antibodies on the response of calves to vaccination against foot and mouth disease. J Hyg (Lond) 1984, 92, 105-116.
20. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014, 5, 446.
21. Patil PK, Sajjanar CM, Nataramanj C, Bayry J. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. Vet Microbiol 2014, 169, 233-235.
22. Polewicz M, Gracia A, Buchanan R, Strom S, Halperin SA, Potter AA, Babiuk LA, Gerds V. Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. Vaccine 2011, 29, 7718-7726.
23. Sadir AM, Schudel AA, Laporte O, Braun M, Margni RA. Response to foot-and-mouth disease vaccines in newborn calves. Influence of age, colostral antibodies and adjuvants. Epidemiol Infect 1988, 100, 135-144.
24. Shankar H, Uppal PK. Immune response of newborn calves to vaccination with foot-and-mouth disease vaccine. Rev Sci Tech Off Int Epiz 1982, 1, 403-414.
25. Späth EJ, Smitsaart E, Casaro AF, Fondevila N, Fernández F, Leunda MR, Compère D, Buffarini M, Pessi H. Immune response of calves to foot-and-mouth disease virus vaccine emulsified with oil adjuvant. Strategies of vaccination. Vaccine 1995, 13, 909-914.
26. Vidor E. Vaccination of newborns against hepatitis A in the presence of maternally derived antibodies. J Comp Pathol 2007, 137 Suppl 1, S42-45.
27. World Organisation for Animal Health (OIE). Foot and mouth disease. In: OIE (ed.). Terrestrial Animal Health Code. 20th ed. pp. 437-463, OIE, Paris, 2011.